Printer Friendly

Millar sells Inca Pressure-Volume (PV) Loop System to the University of Colorado for LVAD heart failure research programme.

M2 EQUITYBITES-June 23, 2017-Millar sells Inca Pressure-Volume (PV) Loop System to the University of Colorado for LVAD heart failure research programme

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Catheter-based, solid-state pressure sensors company Millar Inc announced on Thursday the sale of the CD Leycom Inca Pressure-Volume (PV) Loop System in North America exclusively to the University of Colorado Anschutz Medical Campus

Through this purchase, the University of Colorado will study left ventricular assist devices' (LVADs) impact on ventricular function and post-implantation exercise capacity. Additionally, Dr William Cornwell, assistant professor, Medicine - Cardiology at the University of Colorado Anschutz Medical Campus, observed that some patients continue to experience heart failure symptoms and impaired functional capacity, despite a normalized cardiac output.

Under the five year NIH grant, Dr Cornwell will study the parameters limit exercise capacity in these patients. Analysis of exercise response will be evaluated prior to undergoing LVAD implantation and post LVAD implantation once the patient is clinically ambulatory.

The Inca PV system and high-fidelity pressure-volume catheters will provide a detailed analysis of the impact that LVADs have on RV function. The study will use the Inca PV system, which allows visualization of the complete cardiac cycle in real-time, to monitor ESPVR, EDPVR, Tau and cardiac output.

In addition, Dr Cornwell will be collaborating with Andreas Brieke, MD, medical director of the Mechanical Circulatory Support Programme at the University of Colorado Anschutz Medical Campus, and Greg Coe, MS, Clinical Research Coordinator at the Colorado Clinical Translational Sciences Institute.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 23, 2017
Words:259
Previous Article:Eisai partners with Ewopharma for commercialising Halaven, Targretin and Zonegran in Central Eastern Europe.
Next Article:Lannett wins US FDA approval for Hydrocodone Bitartrate and Acetaminophen Tablets USP in 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters